The same author, in a recently published study, compared the performance of several biomarkers for AKI (including the fractional excretion of sodium, urine and plasma NGAL, urine albumin-to-creatinine ratio, urinary IL-18, kidney injury molecule-1 (KIM-1), TIMP2, IGFBP-7, and uromodulin), with that of FST for the prediction of several clinical end points, including progressive AKI, need for RRT (renal replacement therapy), and inpatient mortality in the same previous published cohort of 77 patients [136]. The gene discussed is HAVCR1; the disease is acute kidney injury.